INS and diabetes mellitus: Circumstantial evidence of an altered β cell phenotype in clinical diabetes was revealed by the observation of co-localization of insulin with glucagon or vimentin (a mesenchymal marker) in a distinct subset of cells in human pancreas sections from subjects with T2D [84, 85].